Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 9:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 803 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Epstein-Barr Virus (EBV) Infection Clear all
Recruiting Phase 1Phase 2 Interventional

Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

NCT06909110
View directory record Official record
Conditions
Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
Interventions
Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, Epstein-Barr Virus Specific T-Lymphocytes
Biological
Lead sponsor
Jessie L. Alexander
Other
Eligibility
1 Month to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 10, 2026, 9:45 PM EDT
Completed Phase 2 Interventional

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease

NCT00003913
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, filgrastim, busulfan, cyclophosphamide, methylprednisolone, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 18 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
23
States / cities
Duarte, California • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 10, 2026, 9:45 PM EDT
Completed Phase 1 Interventional

High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies

NCT00002818
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
cytarabine, deoxycytidine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 10, 2026, 9:45 PM EDT
Recruiting No phase listed Observational

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

NCT01137643
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
biologic sample preservation procedure, cytology specimen collection procedure
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2040
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 10, 2026, 9:45 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

NCT00006125
View directory record Official record
Conditions
Lymphoma
Interventions
doxorubicin hydrochloride, topotecan hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
75
States / cities
Anniston, Alabama • La Jolla, California • San Diego, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 10, 2026, 9:45 PM EDT
Completed Phase 2 Interventional Results available

Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia

NCT03575325
View directory record Official record
Conditions
Lymphoid Leukemia, Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions
CPX-351
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 10, 2026, 9:45 PM EDT
Not listed Phase 1Phase 2 Interventional Results available

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

NCT02481310
View directory record Official record
Conditions
Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, MYC Gene Mutation, Plasmablastic Lymphoma
Interventions
Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride, Etoposide, Ixazomib Citrate, Laboratory Biomarker Analysis, Methotrexate, Prednisone, Rituximab, Therapeutic Hydrocortisone, Vincristine Sulfate
Drug · Other · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Medford, Massachusetts • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Oct 10, 2026, 9:45 PM EDT
Completed Phase 2 Interventional

A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3

NCT00000712
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Acyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
8
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 10, 2026, 9:45 PM EDT
Completed Phase 2 Interventional

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

NCT00055653
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, filgrastim, busulfan, cyclophosphamide, cyclosporine, fludarabine phosphate, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
25
States / cities
Duarte, California • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 10, 2026, 9:45 PM EDT
Recruiting Phase 1 Interventional

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

NCT06034275
View directory record Official record
Conditions
Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome
Interventions
VIP943 (QW), VIP943 (BIW)
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Birmingham, Alabama • Cincinnati, Ohio • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 10, 2026, 9:45 PM EDT
Terminated Phase 1 Interventional

Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

NCT00036855
View directory record Official record
Conditions
AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma
Interventions
rituximab, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan, peripheral blood stem cell transplantation, filgrastim, laboratory biomarker analysis
Biological · Radiation · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 10, 2026, 9:45 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation

NCT00003143
View directory record Official record
Conditions
Lymphoma
Interventions
Amifostine, DHAP
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 10, 2026, 9:45 PM EDT
Completed Phase 1 Interventional

VNP40101M in Treating Patients With Advanced or Metastatic Cancer

NCT00049699
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
laromustine
Drug
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
3
States / cities
New Haven, Connecticut • West Haven, Connecticut • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 10, 2026, 9:45 PM EDT
Completed Phase 1Phase 2 Interventional

Study of @neWorld: A Virtual Community for Children With Cancer

NCT00070421
View directory record Official record
Conditions
Leukemia, Lymphoma, Psychosocial Effects of Cancer and Its Treatment, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
complementary or alternative medicine procedure, management of therapy complications, psychosocial assessment and care
Procedure
Lead sponsor
Leap of Faith Technologies
Industry
Eligibility
10 Years to 15 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Crystal Lake, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 10, 2026, 9:45 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia

NCT07153796
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Mini-CVD, MTX/ARA-C
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 10, 2026, 9:45 PM EDT
Terminated Phase 1 Interventional

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

NCT00725062
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
CD4+CD25+ regulatory T cells, allogeneic hematopoietic stem cell transplantation
Biological · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 10, 2026, 9:45 PM EDT
Completed Phase 3 Interventional Results available

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

NCT00755040
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cyclosporine ophthalmic emulsion, placebo
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
5
States / cities
Palo Alto, California • Chicago, Illinois • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 10, 2026, 9:45 PM EDT
Terminated Phase 1 Interventional

Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma

NCT00383097
View directory record Official record
Conditions
Hodgkins Lymphoma, Non-Hodgkin Lymphoma
Interventions
LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES, LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Oct 10, 2026, 9:45 PM EDT
Recruiting Phase 2 Interventional

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

NCT03314974
View directory record Official record
Conditions
Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myeloproliferative Neoplasms, Myelofibrosis, Myelodysplasia, Refractory Anemia, High Risk Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Lymphoblastic Lymphoma, Burkitt Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, Multiple Myeloma, Juvenile Myelomonocytic Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Natural Killer Cell Malignancies, Acquired Bone Marrow Failure Syndromes
Interventions
HSCT with TBI Regimen, HSCT with Non-TBI Regimen
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 60 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 10, 2026, 9:45 PM EDT
Completed Phase 2 Interventional

Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas

NCT00001237
View directory record Official record
Conditions
Burkitt Lymphoma, Lymphoma, Large-Cell, Diffuse, Lymphoma, Small Noncleaved-Cell
Interventions
granulocyte-macrophage colony stimulating factor (GM-CSF)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 10, 2026, 9:45 PM EDT
Completed Phase 3 Interventional Results available

Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer

NCT00369564
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity, Peripheral Neuropathy, Sarcoma
Interventions
glutamic acid, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
3 Years to 20 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Fort Myers, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 10, 2026, 9:45 PM EDT
Completed Phase 1Phase 2 Interventional

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

NCT00064311
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
ravuconazole
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 10, 2026, 9:45 PM EDT
Active, not recruiting Phase 2 Interventional

A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)

NCT05460533
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
Tisagenlecleucel
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Day to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 10, 2026, 9:45 PM EDT
Completed Phase 2 Interventional

Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer

NCT00255749
View directory record Official record
Conditions
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epoetin alfa
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 10, 2026, 9:45 PM EDT